Astrocyte

CHECK AND CHECKMATE - THE NEW MOLECULAR CHESS
Year
: 2017  |  Volume : 4  |  Issue : 2  |  Page : 108--110

Bedaquiline and delamanid: Sharing the indian experience


Jai B Mullerpattan, Zarir F Udwadia 
 Department of Respiratory Medicine, PD Hinduja National Hospital and Medical Research Center, Mumbai, Maharashtra, India

Correspondence Address:
Zarir F Udwadia
Department of Respiratory Medicine, PD Hinduja National Hospital and Medical Research Centre, Veer Savarkar Marg, Mahim, Mumbai - 400 016, Maharashtra
India

Currently, India is home to the highest number of multi-drug resistant tuberculosis (MDR-TB) patients in the world. Until now, MDR-TB was being treated with repurposed drugs which are toxic and are required to be given for up to 2 years. Two new oral anti-TB drugs, bedaquiline and delamanid have received approval in 2012 and 2014 respectively. While presenting the pharmacology, evidence of efficacy, WHO recommendations, current status of access as well as future directions regarding these two novel anti-TB agents, this paper delves into the India narrative recounting the short clinical experience thus far.


How to cite this article:
Mullerpattan JB, Udwadia ZF. Bedaquiline and delamanid: Sharing the indian experience.Astrocyte 2017;4:108-110


How to cite this URL:
Mullerpattan JB, Udwadia ZF. Bedaquiline and delamanid: Sharing the indian experience. Astrocyte [serial online] 2017 [cited 2022 Aug 19 ];4:108-110
Available from: http://www.astrocyte.in/article.asp?issn=2349-0977;year=2017;volume=4;issue=2;spage=108;epage=110;aulast=Mullerpattan;type=0